The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

MethodologyData used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Reasons to Buy• Establish a comprehensive understanding of the current pipeline scenario across Cannabinoid Receptor Type 2 (CB2) Agonist to formulate effective R&D strategies• Assess challenges and opportunities that influence Cannabinoid Receptor Type 2 (CB2) Agonist research & development (R&D)• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage• Identify and understand the sought after therapy areas and indications for “Cannabinoid Receptor Type 2 (CB2) Agonist• Identify the product attributes and use it for target finding, drug repurposing, and precision medicine• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Cannabinoid Receptor Type 2 (CB2) Agonist to enhance and expand business potential and scope• Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress• Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

This study covers the world outlook for opium and opium-derivative narcotic internal analgesic and antipyretic pharmaceutical preparations across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the...

Global drug screening market projected to grow at a CAGR of 10.2% during the forecast period The drug screening market is expected to reach USD 8.63 billion million by 2022 from USD 5.32 billion in 2017, at a CAGR of 10.2%. Growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing,...

China’s demand for OTC Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...